Navigation Links
ISTA Pharmaceuticals Announces Positive Results for Phase 2 Study of Low-Dose Bromfenac in Dry Eye Disease
Date:6/8/2009

IRVINE, Calif., June 8 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced positive results from a proof-of-concept Phase 2 clinical study in subjects with dry eye disease (keratoconjuctivitis sicca) using a new, proprietary, low-dose formulation of bromfenac, the active ingredient in Xibrom(R) (bromfenac ophthalmic solution) 0.09%. The study achieved statistical significance in the primary endpoint of the objective sign of conjunctival staining (Lissamine Green test) as compared to baseline. The study also achieved statistical significance on the objective sign of corneal staining (Fluorescein test) as compared to baseline. Patients also achieved statistically significant improvements in subjective symptoms measured by the Ocular Surface Disease Index (OSDI) and improvement in patients' most bothersome ocular symptoms.

"The strong clinical results from this proof-of-concept study further support our belief that a modified, low-dose formulation of bromfenac has the potential ability to effectively and conveniently treat signs and symptoms of dry eye disease and provide fast and sustainable relief for patients. Bromfenac's strong safety profile should support long-term treatment, which would be necessitated due to the chronic inflammatory nature of dry eye disease," stated Vicente Anido, Jr., Ph.D., President and Chief Executive Officer of ISTA Pharmaceuticals.

"ISTA is strongly committed to focusing on dry eye disease. The results of this study may help identify patients that would be most suitable for a larger, placebo-controlled study. These data come on the heels of our recently announced positive ecabet sodium Phase 2b study results in ISTA's dry eye franchise. We will analyze the data from both programs to determine which product candidate or candidates to move into further advanced stud
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting
2. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
3. Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
4. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
5. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
6. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
7. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
8. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
9. Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
10. Kinex Pharmaceuticals To Present at ASCO 2009 Annual Meeting
11. TRACON Pharmaceuticals Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... Calif. , May 1, 2015 The ... its 2015 health literacy award winners. The IHA Health ... that make an impact on the practice of educating ... health literacy. IHA gives awards in three categories: innovative ... bestowed its Health Literacy Hero award. In ...
(Date:5/1/2015)... Semler Scientific, Inc. (Nasdaq: SMLR ), ... and markets products that assist healthcare providers in monitoring ... for the first quarter ended March 31, 2015. ... reported continued progress with year over year growth of ... 14%," said Doug Murphy-Chutorian , M.D., chief executive ...
(Date:5/1/2015)... -- Shares of Aerie Pharmaceuticals, Inc. (NASDAQ: AERI ) ... results of the Phase 3 Rocket 1 trail of ... to meet its end points, compelling data from the ... studies. An analyst report on AERI that ... analyst summary, valuation, and recommendation can be viewed by ...
Breaking Medicine Technology:Institute for Healthcare Advancement Announces 2015 Award Winners 2Semler Reports First Quarter 2015 Financial Results 2Semler Reports First Quarter 2015 Financial Results 3Semler Reports First Quarter 2015 Financial Results 4Semler Reports First Quarter 2015 Financial Results 5All is Not Lost for Aerie Pharmaceuticals - VLM Research Issued by BrokerBank Securities, Inc. 2
... FARMINGDALE, N.Y., Feb. 9, 2011 Misonix, Inc. ... company that designs, manufactures, and markets innovative, therapeutic, ... neurosurgery, laparoscopic surgery, and other surgical and medical ... fiscal quarter and six months ending December 31, ...
... SAN FRANCISCO, Feb. 9, 2011 SYNARC, ... to the pharmaceutical and biotechnology industries, announced today that ... and marketing efforts in support of the company,s rapidly ... Ciaran Cooper, a pioneer in the clinical trials ...
Cached Medicine Technology:Misonix Reports Second Quarter and Six Months Fiscal 2011 Financial Results 2Misonix Reports Second Quarter and Six Months Fiscal 2011 Financial Results 3Misonix Reports Second Quarter and Six Months Fiscal 2011 Financial Results 4Misonix Reports Second Quarter and Six Months Fiscal 2011 Financial Results 5Misonix Reports Second Quarter and Six Months Fiscal 2011 Financial Results 6SYNARC Appoints Ciaran Cooper as Vice President, Business Development 2
(Date:5/2/2015)... May 03, 2015 As one of ... the prestigious Safety and Health Achievement and Recognition Program ... to be chosen by the Illinois Department of Labor ... achieved and maintained SHARP certification by the Occupational Safety ... as Essentra has continued to meet or exceed all ...
(Date:5/2/2015)... Vancouver fencing company, QS Fencing, has recently announced ... prospective clients related to their questions on railings and gates. ... their decks and patios. While that seems like an easy ... the person rolls up their sleeve to start working. One ... finding a gate that matches it. , Instead of spending ...
(Date:5/2/2015)... Aliso Viejo, CA (PRWEB) May 02, 2015 ... made exclusively for use in Final Cut Pro X. ... ready for use in Final Cut Pro X . ... a single keyframe with Pixel Film Studios' ProText Kinetic 2. ... drop. Start by staggering two ProText Kinetic presets in ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 We are ... The Delray Recovery Center as one of the Top ... known in the addiction treatment field for their ethics ... to innovate and to continue their educational efforts. The ... workplace environment, never forgetting their purpose – to help ...
(Date:5/2/2015)... On Tuesday April 7th, the patient ... to celebrate improvements in patient care. In 2014 the ... had zero acquired ventilator associated infections, zero central line ... was also recently named a Top Performer by the ... credited the teamwork of staff from all departments involved ...
Breaking Medicine News(10 mins):Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 3Health News:Professional Staff at QS Fencing Company Now Provides Advice on Railings and Gates 2Health News:Pixel Film Studios Announced the Release of Protext Kinetic 2 for FPCX. 2Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:East Liverpool City Hospital Celebrates Patient Care Improvements 2
... Medicare ... ... -- If you’re one of the more than 45 million people relying on Medicare for ... is too expensive, according to Allsup , a nationwide provider of Social Security disability ...
... , , , ... NXTM ), a leading manufacturer of innovative dialysis products, today ... Chief Financial Officer, will be presenting at the UBS Global Life ... Grand Central in New York City. , , ...
... , , BIRMINGHAM, Ala., ... leader in radiology optimization solutions that increase business capacity, productivity ... its Board of Directors has approved changing its name to ... its ability to more accurately represent the precision imaging management ...
... , , FRANKLIN LAKES, N.J., Sept. 1 BD ... that it would present at the following investor healthcare conferences in September: , , ... September 9, 2009, 10:55 ... September 14, 2009, ...
... rank facilities don,t take all measurements into account , TUESDAY, ... onto the U.S. News & World Report list ... in some measurements regarding heart failure, researchers say. , "If ... the areas of heart failure mortality and readmission, you should ...
... , PISCATAWAY, N.J., Sept. 1 Milestone ... advanced injection technologies, today announced that Leslie Bernhard, an independent ... Osser who had previously led the Company as Chairman since ... Chief Executive Officer since February 2009 and was formerly Milestone,s ...
Cached Medicine News:Health News:Allsup Outlines 10 Critical Questions to Answer When Evaluating Medicare Plans 2Health News:Allsup Outlines 10 Critical Questions to Answer When Evaluating Medicare Plans 3Health News:Allsup Outlines 10 Critical Questions to Answer When Evaluating Medicare Plans 4Health News:Allsup Outlines 10 Critical Questions to Answer When Evaluating Medicare Plans 5Health News:NxStage to Present at the UBS Global Life Sciences Conference 2Health News:Optimal Readings Completes Strategic Name Change to Optimal IMX 2Health News:Optimal Readings Completes Strategic Name Change to Optimal IMX 3Health News:Optimal Readings Completes Strategic Name Change to Optimal IMX 4Health News:Optimal Readings Completes Strategic Name Change to Optimal IMX 5Health News:Optimal Readings Completes Strategic Name Change to Optimal IMX 6Health News:Government Best Source for U.S. Hospital Data, Study Finds 2Health News:Milestone Scientific Announces Key Leadership Changes 2Health News:Milestone Scientific Announces Key Leadership Changes 3
... VasoSeal VHD was ... rapidly stop bleeding after ... and radiology procedures. It ... sealing device approved for ...
... collagen hemostat. FirstStop is a non-friable, non-woven ... characteristics. It can easily be cut to ... FirstStop products are not dispersed when wet ... hemostasis is achieved. As the collagen forms ...
InterVascular HemaPatch product line offers the vascular surgeon a range of collagen coated patches in a range of larger sizes angioplasty, or profundaplasty procedures without suture hole bleeding. ...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
Medicine Products: